Women's Super League had record revenues in 2023-24 season
MANCHESTER, England, June 9 (Reuters) - Revenues for Women's Super League (WSL) clubs climbed by 34% to hit 65 million pounds ($88.2 million) for the first time during a record-breaking 2023-24 season, according to analysis from the Deloitte Sports Business Group.
Each of the 12 WSL clubs generated over one million pounds in revenue for the first time, with increases in commercial and match-day revenues contributing to significant growth across the league.
Deloitte is forecasting WSL clubs' total revenue will reach 100 million pounds in the 2025-26 season following the Women's European Championship next month in Switzerland.
Revenues climbed from 48 million pounds in the 2022-23 season, an increase driven by growth in commercial revenue, which now accounts for 40% of WSL clubs' total revenue.
The 2023-24 season came after England finished runners-up to Spain in the 2023 Women's World Cup.
"Women's football in England is evolving rapidly," Tim Bridge, lead partner in the Deloitte Sports Business Group, said in a statement.
"While challenges remain, it is clear there is potential for a passionate and engaged fan base to drive the game's development.
"Capitalising on major international tournaments is important at specific points in time, but sustainable growth hinges on the domestic league's organic development."
The increases were driven mainly by four clubs, with Arsenal (15.3 million), Chelsea (11.5), Manchester United (9.2) and Manchester City (6.6) accounting for about two thirds of the money made across the league.
($1 = 0.7368 pounds)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
16 minutes ago
- Reuters
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
June 9 (Reuters) - Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime. The drug developer, which went public in January, is one of the many that are eyeing the lucrative market of weight-loss drugs that have been dominated by GLP-1 drugs from Novo Nordisk ( opens new tab and Eli Lilly (LLY.N), opens new tab. The drug, MET-233i, helped patients lose 8.4% of their weight, when adjusted for placebo, at 36 weeks. The drug belongs to a class of medicines which mimic the pancreatic hormone amylin that is co-secreted with insulin. It is being developed as a standalone treatment, and in combination with the company's other GLP-1 drug MET-097i. The two hormones combined suppress hunger, help control patients' blood glucose. Metsera's shares, which touched $35.19 in early trading, were up 5% at midday. The first wave of obesity drugs was based mainly on the gut hormone GLP-1, but drugmakers are looking for medicines that target other hormones or help preserve muscle while losing fat for their next generation of drugs. Data from Novo Nordisk's experimental drug CagriSema, which was touted to be the successor of its blockbuster obesity drug Wegovy, has so far fallen below investor expectations. Data from Metsera's 80-patient study showed that its drug has a half life of about 19 days, supporting once-a-month dosing. This compares to the five to seven days for Lilly's Zepbound and Novo's Wegovy that are taken weekly, said Evercore ISI analyst Umer Raffat. The so-called half life of a drug refers to the time it takes for the initial dose of the medicine to decrease by half in a patient's body. It helps determine how frequently a drug should be taken to achieve benefits. Drugmaker AstraZeneca (AZN.L), opens new tab is also testing an amylin-based obesity drug in early trials.
Reuters
2 hours ago
- Reuters
US wholesale inventories in April revised higher
WASHINGTON, June 9 (Reuters) - U.S. wholesale inventories increased in April amid stockpiling of prescription medication in anticipation of tariffs from the Trump administration. Stocks at wholesalers rose 0.2% instead of being unchanged, as estimated last month, the Commerce Department's Census Bureau said on Monday. Economists polled by Reuters had expected last month's estimate would be unrevised. Inventories, a key part of gross domestic product, climbed 0.3% in March. They advanced 2.3% on a year-over-year basis in April. Wholesale stocks of prescription medication surged 1.3% in April. There were also increases in apparel, motor vehicle, groceries and professional equipment inventories. President Donald Trump has said he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients. Apart from drugmakers, businesses front-loaded imports in the first quarter, seeking to avoid Trump's sweeping duties on foreign goods, resulting in a large trade deficit that subtracted a record 4.90 percentage points from GDP. The front-running faded in April, leading to a record decline in imports and the overall trade deficit. While the contraction in the deficit at face value suggests trade could significantly add to gross domestic product in the second quarter, economists say some of the boost could be offset by low inventories. Inventory accumulation increased at a rate of $163.0 billion in the first quarter. The economy contracted at a 0.2% annualized rate in the January-March period, the first GDP decline in three years. It grew at a 2.4% pace in the fourth quarter. Sales at wholesalers edged up 0.1% in April after jumping 0.8% in March. At April's sales pace it would take wholesalers 1.30 months to clear shelves, unchanged from March.
The Guardian
2 hours ago
- The Guardian
Women's Super League clubs hit record-breaking revenues in 2023-24 season
Revenues for Women's Super League (WSL) clubs climbed by 34% to hit £65m during a record-breaking 2023-24 season, according to analysis from the Deloitte Sports Business Group. Each of the 12 WSL clubs generated over £1m in revenue for the first time, with increases in commercial and matchday revenues contributing to significant growth across the league. Deloitte is forecasting WSL clubs' total revenue will reach £100m in the 2025-26 season after the Women's European Championship next month in Switzerland. Revenues climbed from £48m in the 2022-23 season, an increase driven by growth in commercial revenue, which now accounts for 40% of WSL clubs' total revenue. The 2023-24 season came after England finished runners-up to Spain in the 2023 Women's World Cup in Australia and New Zealand. 'Women's football in England is evolving rapidly,' Tim Bridge, lead partner in the Deloitte Sports Business Group, said in a statement. 'While challenges remain, it is clear there is potential for a passionate and engaged fanbase to drive the game's development. 'Capitalising on major international tournaments is important at specific points in time, but sustainable growth hinges on the domestic league's organic development.' Sign up to Moving the Goalposts No topic is too small or too big for us to cover as we deliver a twice-weekly roundup of the wonderful world of women's football after newsletter promotion The increases were driven mainly by four clubs, with Arsenal (£15.3m), Chelsea (£11.5m), Manchester United (£9.2m) and Manchester City (£6.6m) accounting for about two-thirds of the money made across the league.
